Laidlaw Group’s Celgene Corp CELG Stock Holding History

Laidlaw Group’s Portfolio CELG Stock Details CELG Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	$1.8M	Sell	15,600 -1,510	-9%	-$173K	0.86%	40
2015 Q1	$1.97M	Sell	17,110 -420	-2%	-$50.2K	0.94%	38
2014 Q4	$1.96M	Sell	17,530 -550	-3%	-$58K	0.93%	38
2014 Q3	$1.71M	Sell	18,080 -270	-1%	-$24.4K	0.85%	41
2014 Q2	$1.58M	Sell	18,350 -200	-1%	-$15.2K	0.78%	41
2014 Q1	$1.29M	Sell	18,550 -2,748	-13%	-$218K	0.68%	42
2013 Q4	$1.8M	Sell	21,298 -4,632	-18%	-$367K	0.96%	40
2013 Q3	$2M	Sell	25,930 -230	-0.9%	-$16.1K	1.15%	36
2013 Q2	$1.53M	Buy	+26,160	New	+$1.57M	0.86%	38

Other funds holding CELG

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

JSP

Jackson Square Partners Larkspur, California $247M AUM 20.29% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Laidlaw Group's CELG Position: Q2 2015 in Review

Laidlaw Group reduced its Celgene Corp (CELG) stake by 8.8% in Q2 2015, selling an estimated $173K and leaving 15,600 shares worth $1.8M. The position accounts for 0.86% of the portfolio, ranked #40.

Laidlaw Group first reported a position in CELG in Q2 2013 and has held it in 9 quarters since. The position peaked at $2M in Q3 2013. 1,201 funds tracked by Wall St. Rank hold CELG as of Q2 2015.

Laidlaw Group held 15,600 shares of Celgene Corp worth $1.8M as of Q2 2015.
Laidlaw Group sold 1,510 Celgene Corp shares in Q2 2015, an estimated $173K.
Celgene Corp made up 0.86% of Laidlaw Group's portfolio in Q2 2015, its #40 holding.
Laidlaw Group first reported a position in Celgene Corp in Q2 2013 and has held it in 9 quarters since.
Laidlaw Group's Celgene Corp position peaked at $2M in Q3 2013.
1,201 funds tracked by Wall St. Rank held Celgene Corp as of Q2 2015.

Based on Laidlaw Group's 13F filing for Q2 2015, filed 31 Jul 2015.